iShares U.S. Healthcare ETF (NY:IYH)

70.55 +0.15 (+0.21%)

Delayed Quote Updated: 10:00 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares U.S. Healthcare ETF

< Previous 1 2 3 4 Next >

'Barbarism:' AOC Unleashes Fury On US Healthcare System As People Are 'Choosing Between Medicine And Rent' ↗

May 13, 2024

America has one of the highest healthcare costs in the world, with healthcare spending hitting $4.5 trillion in 2022.

Via Benzinga

ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook ↗

May 01, 2024

Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest...

Via Talk Markets

Topics ETFs

Target, Apollo Global Management, Las Vegas Sands And More: CNBC's 'Final Trades' ↗

March 11, 2024

On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors named Apollo Global Management, Inc.

Via Benzinga

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗

December 29, 2023

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

Via Benzinga

Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades' ↗

December 13, 2023

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc (NYSE: SHAK)

Via Benzinga

Cigna Drops Humana Merger, Opts For $10 Billion Buyback Strategy ↗

December 10, 2023

In a recent development in the health insurance sector, Cigna Corporation (NYSE: CI) has withdrawn from its proposed merger with Humana Inc. (NYSE:

Via Benzinga

Humana, Comerica, Cleveland-Cliffs, And More: CNBC's 'Final Trades' ↗

December 04, 2023

On CNBC’s "Halftime Report Final Trades," Shannon Saccocia of Boston Private named iShares U.S.

Via Benzinga

Cisco, Burlington Stores, Broadcom And More On CNBC's 'Final Trades' ↗

November 24, 2023

It has been "a really tough year" for the healthcare sector. That's according to Shannon Saccocia of Boston Private, who appeared on CNBC’s "Halftime Report Final Trades."

Via Benzinga

Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups ↗

October 05, 2023

A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments.

Via Benzinga

All eyes on the Fed as inflation metrics give mixed signals ↗

September 19, 2023

Although the FOMC will almost certainly keep the Fed funds rate steady this week, investors aren’t yet convinced that the rate hike cycle has ended.

Via Talk Markets

Topics Economy

Beyond The Hustle: Embracing Ancient Chinese Wisdom To Combat Modern Day Burnout ↗

August 17, 2023

In our modern, high-speed society, many find themselves exhausted in the relentless chase for achievement. Yet, a concept from ancient China that dates back 2,000 years might offer a path to...

Via Benzinga

4 Top-Ranked Sector ETFs To Buy In The Second Half ↗

July 12, 2023

Investors could be well served by ETFs from sectors that house the top-ranked industries.

Via Talk Markets

From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs ↗

July 07, 2023

Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as...

Via Benzinga

The 3 Most Promising Industries to Invest in for 2023’s Second Half ↗

June 27, 2023

Discover the most promising industries to invest in. Unlock the top sectors for investing and seize lucrative opportunities.

Via InvestorPlace

Stocks Flounder Despite Inflation Downtrend As Banking Crisis Emerges, But Outlook Remains Encouraging ↗

March 17, 2023

Nothing goes in a straight line for long, and inflation is no different, i.e., the path is volatile, but disinflationary trends remain intact.

Via Talk Markets

Got $10,000? Buy These 2 Market-Beating ETFs for the Long Haul ↗

February 15, 2023

These exchange-traded funds have soundly beaten the S&P 500 over the past 10 years.

Via The Motley Fool

Uncertainties On Fed Policy, Geopolitics, And Earnings Cloud 2023 Outlook, But Trends Are Promising ↗

January 17, 2023

The future direction of both stocks and bonds hinges on the trajectory of corporate earnings and interest rates, both of which are largely at the mercy of inflation, Fed monetary policy, and the state...

Via Talk Markets

Worried About 2023? Here's a Safer Way to Invest in Stocks This Year ↗

January 04, 2023

By holding a broad range of stocks and spreading out your investment over the year, you can minimize your overall risk.

Via The Motley Fool

The 3 Best Sectors to Invest in for 2023 ↗

December 28, 2022

A blend of value and growth defines the best sectors to invest in for 2023. These three sectors best fit the definition.

Via InvestorPlace

Health Care Exposure Ahead Of CPI Data, Progressive, Dollar General And Seagate Technology Feature On CNBC's 'Final Trades' ↗

October 13, 2022

On CNBC’s “Halftime Report Final Trades,” Courtney Garcia of Payne Capital Management said that health care is going to be among the outperformers.

Via Benzinga

Investors Await Bullish Catalysts As Inflation, Interest Rates, And Money Supply Growth Show Signs Of Topping ↗

June 30, 2022

Although the Fed likely will raise rates another 50-75 bps in July, it will not raise as much as the market is pricing in, and indeed the Fed may instead be forced to ease later this year or early next...

Via Talk Markets

CNBC's Final Trades: Microsoft, US Dollar Index, iShares Healthcare ETF And This Cybersecurity Tech Major ↗

January 20, 2022

On CNBC’s “Halftime Report Final Trades

Via Benzinga

Adobe Earnings Strangle Trade ↗

December 11, 2021

Adobe announces earnings this week, and we plan on using an options strategy called a

Via Talk Markets

Why WHO Did Not Recommend Convalescent Plasma Therapy For COVID-19 ↗

December 07, 2021

The World Health Organization said that it's not recommending the use of convalescent plasma as a treatment for COVID-19 for mild or severe cases. The treatment uses...

Via Benzinga

New Drug Applications Pile Up With FDA As Pandemic Still Sore Spot For Delayed Inspections ↗

November 23, 2021

The FDA continues to face a backlog of drug manufacturing facility inspections. A total of 52 new drug (but no biologics) applications remain delayed due to the backlog...

Via Benzinga

Entering Q4 with mix of optimism and caution suggests hedged long positioning ↗

October 19, 2021

While the cap-weighted indexes have surged to new highs as recently as early September, the equal-weight and small-cap indexes have been trading sideways since March.

Via Talk Markets

4 Defensive Sector ETFs to Protect Your Portfolio ↗

October 08, 2021

A myriad of concerns has made investors jittery, resulting in a flight to defensive sectors like utilities, real estate, healthcare, and consumer staples.

Via Talk Markets

J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data ↗

September 25, 2021

Johnson & Johnson has again announced positive data highlighting the efficiency of its single-shot COVID-19 vaccine in providing protection against COVID-related hospitalizations.

Via Talk Markets

5 ETF Areas for Investors to Consider Amid the September Slump ↗

September 23, 2021

Wall Street is witnessing a tough time in the historically weak month of September.

Via Talk Markets

Blowout earnings, low interest rates, and dovish Fed, but have stocks hit a peak? ↗

September 09, 2021

Another positive month for the major indexes, despite plenty of new bricks in the proverbial Wall of Worry.

Via Talk Markets

Topics Economy

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.